1. The instrument
The GAD-7 is a self-report screening instrument designed to identify probable generalized anxiety disorder in primary-care and general-population settings. It was developed by Robert L. Spitzer, Kurt Kroenke, Janet B. W. Williams, and Bernd Löwe in 2006 and published in Archives of Internal Medicine. It is the most widely-used brief anxiety screen worldwide, with over 40,000 citations across the clinical literature.
The instrument was developed by starting with a 13-item pool derived from DSM-IV criteria for GAD plus other anxiety measure items. The 7 items with the highest correlation to total score were selected, prioritizing brevity and clinical utility for primary-care contexts where screening time is limited.
The GAD-7 is published with permissive licensing — Pfizer (the original sponsor) granted explicit permission to reproduce, translate, display, or distribute the instrument without charge. This contrasts with several other anxiety instruments that carry commercial licensing fees.
2. The 7 items
Over the last 2 weeks, how often have you been bothered by the following problems?
| # | Item | Score range |
|---|---|---|
| 1 | Feeling nervous, anxious, or on edge | 0–3 |
| 2 | Not being able to stop or control worrying | 0–3 |
| 3 | Worrying too much about different things | 0–3 |
| 4 | Trouble relaxing | 0–3 |
| 5 | Being so restless that it is hard to sit still | 0–3 |
| 6 | Becoming easily annoyed or irritable | 0–3 |
| 7 | Feeling afraid as if something awful might happen | 0–3 |
Response options: 0 = Not at all, 1 = Several days, 2 = More than half the days, 3 = Nearly every day. Total score range: 0–21.
3. Scoring and severity bands
The GAD-7 total score is the simple sum of the 7 item responses. There are no reverse-coded items and no weighting. Standard severity bands per Spitzer et al. 2006:
- 0–4 Minimal anxiety. Symptoms unlikely to indicate clinically significant anxiety.
- 5–9 Mild anxiety. Some symptoms present, subthreshold for GAD.
- 10–14 Moderate anxiety. Probable GAD per the standard cutoff.
- 15–21 Severe anxiety. High symptom burden; professional consultation strongly recommended.
The standard cutoff of ≥10 is used in NHS IAPT (Improving Access to Psychological Therapies), VA/DoD Clinical Practice Guidelines, and APA Anxiety Disorder Treatment Guidelines. Plummer et al. 2016 meta-analysis suggested cutoff ≥8 may optimize sensitivity-specificity in some contexts; the tool uses ≥10 because it is the most-cited and clinically-established cutpoint.
4. Validation evidence
| Property | Value | Source |
|---|---|---|
| Sensitivity at cutoff ≥10 | 89% | Spitzer et al. 2006 |
| Specificity at cutoff ≥10 | 82% | Spitzer et al. 2006 |
| Cronbach's α (internal consistency) | 0.92 | Spitzer et al. 2006, n=2,740 |
| Test-retest reliability (1-week) | ICC 0.83 | Spitzer et al. 2006 |
| NPV at cutoff ≥10 | 0.97 | Löwe et al. 2008 |
| General population mean | 3.0 (SD 3.5) | Hinz et al. 2017, n=5,036 |
| Primary care mean | 6.1 (SD 4.7) | Spitzer et al. 2006 |
| Psychiatric outpatient mean | 11.6 (SD 5.4) | Beard & Björgvinsson 2014 |
The GAD-7 has been translated and validated in over 30 languages, including Spanish, Mandarin, Korean, Arabic, Portuguese, German, French, Japanese, Hindi, and Swahili. Validation studies in non-Western populations generally support the instrument's reliability (Cronbach's α typically >0.85) though specific cutoff values may differ by population.
5. Limitations of the screen
- Not diagnostic. The GAD-7 is a screen, not a diagnosis. A score of 10+ is a strong signal that anxiety symptoms warrant clinical attention, but only a qualified professional can diagnose GAD via DSM-5 or ICD-11 clinical interview.
- Captures last 2 weeks only. Anxiety naturally fluctuates with life events. A snapshot during a stressful period may overstate; a snapshot during a calm period may understate.
- Sensitive to multiple anxiety disorders. Per Kroenke et al. 2007, the GAD-7 also screens panic disorder (sens 74%), social anxiety disorder (sens 72%), and PTSD (sens 66%) at ≥10. Useful for transdiagnostic screening but a limitation for GAD-specific case finding.
- Self-report dependent. Self-criticism, alexithymia, denial, recall bias, or aspirational responding can distort scores.
- Specificity drops in psychiatric samples. Beard & Björgvinsson 2014 found cutoff ≥10 had only 79.5% sensitivity in heterogeneous psychiatric outpatients, with high false-positive rates for non-GAD anxiety disorders.
- Cultural variation. The instrument was developed in US/European primary care. Cultural expression of anxiety varies, and somatic-vs-cognitive emphasis differs across cultures.
6. Related concepts
7. References
- Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine, 166(10), 1092–1097. doi.org/10.1001/archinte.166.10.1092
- Löwe, B., Decker, O., Müller, S., et al. (2008). Validation and standardization of the GAD-7 in the general population. Medical Care, 46(3), 266–274. doi.org/10.1097/MLR.0b013e318160d093
- Hinz, A., Klein, A. M., Brähler, E., et al. (2017). Psychometric evaluation of the GAD-7. Journal of Affective Disorders, 210, 338–344. doi.org/10.1016/j.jad.2016.12.012
- Plummer, F., Manea, L., Trepel, D., & McMillan, D. (2016). Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. General Hospital Psychiatry, 39, 24–31. doi.org/10.1016/j.genhosppsych.2015.11.005
- Kroenke, K., Spitzer, R. L., Williams, J. B. W., Monahan, P. O., & Löwe, B. (2007). Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Annals of Internal Medicine, 146(5), 317–325. doi.org/10.7326/0003-4819-146-5-200703060-00004
- Beard, C., & Björgvinsson, T. (2014). Beyond generalized anxiety disorder: psychometric properties of the GAD-7 in a heterogeneous psychiatric sample. Journal of Anxiety Disorders, 28(6), 547–552. doi.org/10.1016/j.janxdis.2014.06.002